PURPOSE: This study aims to investigate the role of the aberrant expression of Transkelolase-like 1 (TKTL1) in head and neck squamous cell carcinoma (HNSCC) tumorigenesis and to characterize TKTL1 contribution to HNSCC tumorigenesis through aerobic glycolysis and HIF1alpha stabilization. EXPERIMENTAL DESIGN: TKTL1 promoter hypomethylation and mRNA/protein aberrant expression were studied in human HNSCC tumor samples and normal mucosas. Oncogenic functions of TKTL1 were examined in HNSCC cell line panels and tumor xenograft models with TKTL1 expression construct. The metabolite levels of fructose-6-phosphate, glyceraldehydes-3-phosphate, pyruvate, lactate, and the levels of HIF1alpha protein and its downsteam glycolytic targets were compared between the TKTL1-expressing and vehicle-expressing HNSCC cells. Meanwhile, the effects of HIF1alpha/glycolytic inhibitors were evaluated on the TKTL1 transfectants. RESULTS: TKTL1 exhibits high frequency of promoter hypomethylation in HNSCC tumors compared with the normal mucosas, correlating with its overexpression in HNSCC. Overexpression of TKTL1 in HNSCC cells promoted cellular proliferation and enhanced tumor growth in vitro and in vivo. Overexpression of TKTL1 increased the production of fructose-6-phosphate and glyceraldehyde-3-phosphate, in turn elevating the production of pyruvate and lactate, resulting in the normoxic stabilization of the malignancy-promoting transcription factor HIF1alpha and the upregulation of downstream glycolytic enzymes. Notably, the reduction of TKTL1 expression decreased HIF1alpha accumulation and inhibition with HIF1alpha and/or the glycolysis inhibitor could abrogate the growth effects mediated by TKTL1 overexpression. CONCLUSION: TKTL1 is a novel candidate oncogene that is epigenetically activated by aberrant hypomethlation and contributes to a malignant phenotype through altered glycolytic metabolism and HIF1alpha accumulation.
PURPOSE: This study aims to investigate the role of the aberrant expression of Transkelolase-like 1 (TKTL1) in head and neck squamous cell carcinoma (HNSCC) tumorigenesis and to characterize TKTL1 contribution to HNSCC tumorigenesis through aerobic glycolysis and HIF1alpha stabilization. EXPERIMENTAL DESIGN:TKTL1 promoter hypomethylation and mRNA/protein aberrant expression were studied in humanHNSCC tumor samples and normal mucosas. Oncogenic functions of TKTL1 were examined in HNSCC cell line panels and tumor xenograft models with TKTL1 expression construct. The metabolite levels of fructose-6-phosphate, glyceraldehydes-3-phosphate, pyruvate, lactate, and the levels of HIF1alpha protein and its downsteam glycolytic targets were compared between the TKTL1-expressing and vehicle-expressing HNSCC cells. Meanwhile, the effects of HIF1alpha/glycolytic inhibitors were evaluated on the TKTL1 transfectants. RESULTS:TKTL1 exhibits high frequency of promoter hypomethylation in HNSCC tumors compared with the normal mucosas, correlating with its overexpression in HNSCC. Overexpression of TKTL1 in HNSCC cells promoted cellular proliferation and enhanced tumor growth in vitro and in vivo. Overexpression of TKTL1 increased the production of fructose-6-phosphate and glyceraldehyde-3-phosphate, in turn elevating the production of pyruvate and lactate, resulting in the normoxic stabilization of the malignancy-promoting transcription factor HIF1alpha and the upregulation of downstream glycolytic enzymes. Notably, the reduction of TKTL1 expression decreased HIF1alpha accumulation and inhibition with HIF1alpha and/or the glycolysis inhibitor could abrogate the growth effects mediated by TKTL1 overexpression. CONCLUSION:TKTL1 is a novel candidate oncogene that is epigenetically activated by aberrant hypomethlation and contributes to a malignant phenotype through altered glycolytic metabolism and HIF1alpha accumulation.
Authors: Noan-Minh Chau; Paul Rogers; Wynne Aherne; Veronica Carroll; Ian Collins; Edward McDonald; Paul Workman; Margaret Ashcroft Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: Jihye Yun; Carlo Rago; Ian Cheong; Ray Pagliarini; Philipp Angenendt; Harith Rajagopalan; Kerstin Schmidt; James K V Willson; Sandy Markowitz; Shibin Zhou; Luis A Diaz; Victor E Velculescu; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos Journal: Science Date: 2009-08-06 Impact factor: 47.728
Authors: Yutaka Tokumaru; Keishi Yamashita; Motonobu Osada; Shuji Nomoto; Dong-Il Sun; Yan Xiao; Mohammad Obaidul Hoque; William H Westra; Joseph A Califano; David Sidransky Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Carmela Ricciardelli; Noor A Lokman; Sowmya Cheruvu; Izza A Tan; Miranda P Ween; Carmen E Pyragius; Andrew Ruszkiewicz; Peter Hoffmann; Martin K Oehler Journal: Clin Exp Metastasis Date: 2015-04-21 Impact factor: 5.150
Authors: Keith R Laderoute; Joy M Calaoagan; Wan-Ru Chao; Dominc Dinh; Nicholas Denko; Sarah Duellman; Jessica Kalra; Xiaohe Liu; Ioanna Papandreou; Lidia Sambucetti; Laszlo G Boros Journal: J Biol Chem Date: 2014-07-03 Impact factor: 5.157